Something to note: oral treatment & if successful:
https://www.google.com.au/amp/s/www.nytimes.com/2021/10/17/health/covid-treatment-access-molnupiravir.amp.html
3% vaccination rate across Africa, quoted in this article. That’s appalling. Oral treatments for COVID-19 should know no boundaries. They don’t need cold-chain nor expense or expertise to hospitals administering IV expensive MABS. Other Drug companies (ie Merck) will allow out-licensing with cheaper cost to Govts/patients for oral antivirals +/- WHO support.
https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/
Interesting article above on Molnupiravir trials in India.
GLTAH
- Forums
- ASX - By Stock
- DXB
- DXB Chart
DXB Chart, page-118
-
-
- There are more pages in this discussion • 884 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
55.5¢ |
Change
-0.015(2.63%) |
Mkt cap ! $305.1M |
Open | High | Low | Value | Volume |
56.0¢ | 58.5¢ | 54.0¢ | $3.231M | 5.779M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1118 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.5¢ | 239062 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1118 | 0.555 |
3 | 56053 | 0.550 |
6 | 111652 | 0.545 |
15 | 259396 | 0.540 |
4 | 69275 | 0.535 |
Price($) | Vol. | No. |
---|---|---|
0.565 | 239062 | 1 |
0.570 | 95670 | 3 |
0.575 | 33246 | 2 |
0.580 | 11000 | 1 |
0.585 | 74555 | 5 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online